| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 621.7 | 593.8 |
| Gross profit | 275.0 | 270.3 |
| Profit before tax | -151.0 | -7.1 |
| Net income | -167.0 | -55.8 |
| EPS (diluted, $ a share) | $-3.70 | $-1.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +4.7% |
|---|---|
| Gross margin | 44.2% |
| Operating margin | -28.1% |
10-K filed with the SEC, NASDAQ: AZTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Azenta, Inc.: key numbers
- Share price
- $44.80Close, Nov 20
- Market cap
- $1.98B
- Shares outstanding
- 41.94MLatest SEC cover page
- Sector
- Technology
- Industry
- Special Industry Machinery, NECSIC 3559
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Azenta, Inc.
All →Azenta Financial Results
Azenta reported fiscal fourth quarter and full year 2026 results, with Q4 revenue growing 5% year-over-year to $167 million. The company completed the sale of its B Medical Systems business during the year and is focusing on driving organic growth and profitability in its Multiomics and Sample Management segments for fiscal 2027.
- Term
- FY2026
“We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency.”
Dr. Martin Madaus, Interim President and Chief Executive Officer
“Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives.”
Dr. Martin Madaus, Interim President and Chief Executive Officer
Azenta Signs $71M M&A Deal with SynPlexity Inc.
Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.
- Value
- $71M
- Counterparty
- SynPlexity Inc.
- Term
- 5 years
Azenta Business Update
Azenta, Inc. announced a restructuring plan for its Multiomics segment involving workforce reductions and the closure of three North American laboratory sites. The company expects to incur pre-tax charges between $11 million and $13 million, including $9 million in asset impairments, while targeting $11 million in annualized cost savings.
Azenta Executive Compensation
Azenta, Inc. entered into a letter agreement with Dr. Martin D. Madaus setting his compensation as Interim President and CEO, including a $600,000 base salary, a 100% cash performance bonus, and $1.2 million in restricted stock units. Additionally, the company approved one-time RSU retention awards for other named executive officers, including $1.0 million for CFO Lawrence Lin.
- Counterparty
- Dr. Martin D. Madaus
- Term
- 1 year